MX2017010772A - Terapia de gen para mejorar la vision. - Google Patents
Terapia de gen para mejorar la vision.Info
- Publication number
- MX2017010772A MX2017010772A MX2017010772A MX2017010772A MX2017010772A MX 2017010772 A MX2017010772 A MX 2017010772A MX 2017010772 A MX2017010772 A MX 2017010772A MX 2017010772 A MX2017010772 A MX 2017010772A MX 2017010772 A MX2017010772 A MX 2017010772A
- Authority
- MX
- Mexico
- Prior art keywords
- photoreceptor
- gene therapy
- improve vision
- cane
- light
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201503008A GB201503008D0 (en) | 2015-02-23 | 2015-02-23 | Treatment |
| PCT/GB2016/050419 WO2016135457A1 (en) | 2015-02-23 | 2016-02-19 | Gene therapy to improve vision |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017010772A true MX2017010772A (es) | 2018-03-01 |
Family
ID=52822045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010772A MX2017010772A (es) | 2015-02-23 | 2016-02-19 | Terapia de gen para mejorar la vision. |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20180030477A1 (enExample) |
| EP (1) | EP3261679B1 (enExample) |
| JP (1) | JP6771474B2 (enExample) |
| KR (1) | KR102272466B1 (enExample) |
| CN (1) | CN107530449A (enExample) |
| AU (2) | AU2016225277B2 (enExample) |
| CA (1) | CA2977464C (enExample) |
| CY (1) | CY1126098T1 (enExample) |
| DK (1) | DK3261679T3 (enExample) |
| EA (1) | EA201791900A1 (enExample) |
| ES (1) | ES2947308T3 (enExample) |
| FI (1) | FI3261679T3 (enExample) |
| GB (1) | GB201503008D0 (enExample) |
| HK (1) | HK1248594A1 (enExample) |
| HR (1) | HRP20230775T1 (enExample) |
| HU (1) | HUE062319T2 (enExample) |
| IL (1) | IL254066B (enExample) |
| LT (1) | LT3261679T (enExample) |
| MX (1) | MX2017010772A (enExample) |
| MY (1) | MY186444A (enExample) |
| PH (1) | PH12017501525B1 (enExample) |
| PL (1) | PL3261679T3 (enExample) |
| PT (1) | PT3261679T (enExample) |
| RS (1) | RS64372B1 (enExample) |
| SG (2) | SG11201706822XA (enExample) |
| SI (1) | SI3261679T1 (enExample) |
| SM (1) | SMT202300200T1 (enExample) |
| WO (1) | WO2016135457A1 (enExample) |
| ZA (1) | ZA201706440B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3516046B1 (en) * | 2016-09-22 | 2022-07-13 | Sorbonne Université | Optogenetically transformed photoreceptor precursor cells for the use in the treatment of retinal degenerative diseases |
| JP2024524600A (ja) * | 2021-07-06 | 2024-07-05 | インスティテュート オブ モレキュラー アンド クリニカル オフサルモロジー バーゼル | 桿体光受容体における遺伝子の特異的発現のためのプロモーター |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2442670A1 (en) * | 2001-04-13 | 2002-10-24 | The Trustees Of The University Of Pennsylvania | Method of treating or retarding the development of blindness |
| EP3437473A1 (en) * | 2006-05-04 | 2019-02-06 | Wayne State University | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids |
| PT2271369E (pt) * | 2008-04-18 | 2014-07-10 | Novartis Forschungsstiftung | Novas ferramentas terapêuticas e métodos para tratar a cegueira |
| US20140099284A1 (en) * | 2010-10-15 | 2014-04-10 | Eos Neuroscience, Inc | Modulation neural pathways |
| US8957028B2 (en) * | 2010-11-13 | 2015-02-17 | Massachusetts Institute Of Technology | Red-shifted opsin molecules and uses thereof |
| WO2012167109A2 (en) * | 2011-06-03 | 2012-12-06 | Massachusetts Eye & Ear Infirmary | Rpgrip1 gene therapy for leber congenital amaurosis |
| WO2013124477A1 (en) * | 2012-02-24 | 2013-08-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of retinal degenerative diseases |
| US20170182191A1 (en) * | 2014-07-29 | 2017-06-29 | Circuit Therapeutics, Inc. | System and method for optogenetic therapy |
-
2015
- 2015-02-23 GB GB201503008A patent/GB201503008D0/en not_active Ceased
-
2016
- 2016-02-19 RS RS20230560A patent/RS64372B1/sr unknown
- 2016-02-19 PH PH1/2017/501525A patent/PH12017501525B1/en unknown
- 2016-02-19 KR KR1020177026938A patent/KR102272466B1/ko active Active
- 2016-02-19 SG SG11201706822XA patent/SG11201706822XA/en unknown
- 2016-02-19 EA EA201791900A patent/EA201791900A1/ru unknown
- 2016-02-19 HR HRP20230775TT patent/HRP20230775T1/hr unknown
- 2016-02-19 SI SI201631710T patent/SI3261679T1/sl unknown
- 2016-02-19 PL PL16706413.8T patent/PL3261679T3/pl unknown
- 2016-02-19 AU AU2016225277A patent/AU2016225277B2/en active Active
- 2016-02-19 LT LTEPPCT/GB2016/050419T patent/LT3261679T/lt unknown
- 2016-02-19 WO PCT/GB2016/050419 patent/WO2016135457A1/en not_active Ceased
- 2016-02-19 MX MX2017010772A patent/MX2017010772A/es unknown
- 2016-02-19 EP EP16706413.8A patent/EP3261679B1/en active Active
- 2016-02-19 ES ES16706413T patent/ES2947308T3/es active Active
- 2016-02-19 FI FIEP16706413.8T patent/FI3261679T3/fi active
- 2016-02-19 HU HUE16706413A patent/HUE062319T2/hu unknown
- 2016-02-19 PT PT167064138T patent/PT3261679T/pt unknown
- 2016-02-19 JP JP2017544639A patent/JP6771474B2/ja active Active
- 2016-02-19 MY MYPI2017001247A patent/MY186444A/en unknown
- 2016-02-19 HK HK18108485.5A patent/HK1248594A1/zh unknown
- 2016-02-19 CN CN201680023264.6A patent/CN107530449A/zh active Pending
- 2016-02-19 SM SM20230200T patent/SMT202300200T1/it unknown
- 2016-02-19 US US15/552,737 patent/US20180030477A1/en not_active Abandoned
- 2016-02-19 SG SG10202005923WA patent/SG10202005923WA/en unknown
- 2016-02-19 DK DK16706413.8T patent/DK3261679T3/da active
- 2016-02-19 CA CA2977464A patent/CA2977464C/en active Active
-
2017
- 2017-08-20 IL IL254066A patent/IL254066B/en unknown
- 2017-09-22 ZA ZA2017/06440A patent/ZA201706440B/en unknown
-
2020
- 2020-02-21 US US16/797,527 patent/US20200377907A1/en not_active Abandoned
-
2022
- 2022-03-07 AU AU2022201553A patent/AU2022201553B2/en active Active
-
2023
- 2023-07-21 CY CY20231100352T patent/CY1126098T1/el unknown
-
2025
- 2025-06-04 US US19/228,304 patent/US20250290096A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001522A1 (es) | Focalización de péptidos para dirigir virus adenoasociados (aavs) | |
| AR099837A1 (es) | Terapia génica para la retinitis pigmentaria | |
| CO2019000395A2 (es) | Genes de mini–distrofina optimizados y casetes de expresión y su uso | |
| CO2018004564A2 (es) | Genes de ataxia de friedreich modificados y vectores para terapia génica | |
| MX2016014248A (es) | Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton. | |
| CL2017001296A1 (es) | Anticuerpos contra cd73 y sus usos | |
| MX2016015456A (es) | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos. | |
| MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
| ZA201705628B (en) | Methods and compositions for treating genetic eye diseases | |
| MA40902A (fr) | Vaccins hpv16 thérapeutiques | |
| MX2019008755A (es) | Variantes de hsd17b13 y usos de las mismas. | |
| EA201790734A1 (ru) | Конденсированные пентациклические производные имидазола | |
| EA201790405A1 (ru) | Композиции и способы лечения метаболических расстройств | |
| EP3270728A4 (en) | Anti-sprain and shock-absorbing balance sole and footgear | |
| CY1123031T1 (el) | Ρυθμιστες της δραστικοτητας του συμπληρωματος | |
| EA201692512A1 (ru) | Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки | |
| CY1123793T1 (el) | Γονιδιακη θεραπεια rpgr για μελαγχρωστικη αμφιβληστροειδοπαθεια | |
| CY1124195T1 (el) | Συμπληρωματικα θεραπευτικα σκευασματα για την διαδοχικη ή ξεχωριστη χορηγηση βουτυρικου οξεος και προβιοτικων | |
| WO2017106899A3 (en) | Therapeutic methods using erythrocytes | |
| MX2020004666A (es) | Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares. | |
| BR112017005235A2 (pt) | vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc) | |
| EA201792399A1 (ru) | Пептидные композиции и способы использования | |
| CY1126098T1 (el) | Γονιδιακη θεραπεια για τη βελτιωση της ορασης | |
| BR112018010155A2 (pt) | segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca | |
| MX2021008941A (es) | Moduladores gpr35. |